About | Home | Search
Pubget
Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Drug Therapy (26):
  • Thrombolytic Therapy
  • Self Administration
  • Drug Therapy, Combination
  • Drug Dosage Calculations
  • Sclerotherapy
  • Photochemotherapy
  • Hormone Replacement Therapy
  • Drug Delivery Systems
  • Self Medication
  • Premedication
  • Electrochemotherapy
  • Antineoplastic Protocols
  • Enema
  • Chemoprevention
  • Medication Errors
  • Polypharmacy
  • Pleurodesis
  • Drug Administration Routes
  • Fluid Therapy
  • Drug Therapy, Computer-Assisted
  • Drug Prescriptions
  • Chemotherapy, Adjuvant
  • Orthomolecular Therapy
  • Drug Administration Schedule
  • Home Infusion Therapy
  • Chelation Therapy
Home > Therapeutics > Drug Therapy

Recent article

Drug Therapy

JAMA (307)2 2012
Supplementation in acute lung injury.
Klemens König, Peter Rosenberger and Valbona Mirakaj
Abstract
PMID: 22235080

Large_pdficon_selected PDF is available here.
< More recent Older article >
JAMA (307)2 2012
Supplementation in acute lung injury.
Bruce Ryan Bistrian
Abstract
PMID: 22235079

Large_pdficon_selected PDF is available here.
JAMA (307)2 2012
Supplementation in acute lung injury.
Thomas W Felbinger, Markus A Weigand and Konstantin Mayer
Abstract
PMID: 22235078

Large_pdficon_selected PDF is available here.
Korean Journal of Gastroenterology (58)2 2011
[A case of pegylated interferon alpha-2a monotherapy in a peritoneal dialysis patient with chronic hepatitis C].
Hye Jin Tae, Dae Won Jun, Jong Wook Choi, Woong Jun Kim, Bong Young Kim, Joo Hyun Sohn and Min Ho Lee
Abstract
We experienced a case of a peritoneal dialysis patient with chronic hepatitis C who was successfully treated with PEG-IFN monotherapy. A 50-year old man was undergoing peritoneal dialysis because of diabetic nephropathy. Considering that his HCV genotype was 2, we decided to treat him with PEG-IFN a... | PMID: 21873827

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Pádraig D'Arcy, Slavica Brnjic, Maria Hägg Olofsson, Mårten Fryknäs, Kristina Lindsten, Michelandrea De Cesare, Paola Perego, Behnam Sadeghi, Moustapha Hassan, Rolf Larsson and Stig Linder
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH... | PMID: 22057347

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Pádraig D'Arcy, Slavica Brnjic, Maria Hägg Olofsson, Mårten Fryknäs, Kristina Lindsten, Michelandrea De Cesare, Paola Perego, Behnam Sadeghi, Moustapha Hassan, Rolf Larsson and Stig Linder
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH... | PMID: 22057347

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Pádraig D'Arcy, Slavica Brnjic, Maria Hägg Olofsson, Mårten Fryknäs, Kristina Lindsten, Michelandrea De Cesare, Paola Perego, Behnam Sadeghi, Moustapha Hassan, Rolf Larsson and Stig Linder
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH... | PMID: 22057347

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
Merit Cudkowicz, Michael E Bozik, Evan W Ingersoll, Robert Miller, Hiroshi Mitsumoto, Jeremy Shefner, Dan H Moore, David Schoenfeld, James L Mather, Donald Archibald, Mary Sullivan, Craig Amburgey, Juliet Moritz and Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In... | PMID: 22101764

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
Merit Cudkowicz, Michael E Bozik, Evan W Ingersoll, Robert Miller, Hiroshi Mitsumoto, Jeremy Shefner, Dan H Moore, David Schoenfeld, James L Mather, Donald Archibald, Mary Sullivan, Craig Amburgey, Juliet Moritz and Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In... | PMID: 22101764

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
Merit Cudkowicz, Michael E Bozik, Evan W Ingersoll, Robert Miller, Hiroshi Mitsumoto, Jeremy Shefner, Dan H Moore, David Schoenfeld, James L Mather, Donald Archibald, Mary Sullivan, Craig Amburgey, Juliet Moritz and Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In... | PMID: 22101764

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
New HCV drugs trigger race for more tolerable therapies.
Sarah C P Williams
Abstract
PMID: 22146431

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
New HCV drugs trigger race for more tolerable therapies.
Sarah C P Williams
Abstract
PMID: 22146431

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
New HCV drugs trigger race for more tolerable therapies.
Sarah C P Williams
Abstract
PMID: 22146431

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Four-in-one HIV pill may be exception among combination drugs.
Hannah Waters
Abstract
PMID: 22146434

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Four-in-one HIV pill may be exception among combination drugs.
Hannah Waters
Abstract
PMID: 22146434

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Four-in-one HIV pill may be exception among combination drugs.
Hannah Waters
Abstract
PMID: 22146434

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Class of once-weekly diabetes drugs poised for approval.
Hannah Waters
Abstract
PMID: 22146435

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Class of once-weekly diabetes drugs poised for approval.
Hannah Waters
Abstract
PMID: 22146435

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Class of once-weekly diabetes drugs poised for approval.
Hannah Waters
Abstract
PMID: 22146435

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Patent-sharing scheme for neglected diseases may have catch.
Hannah Waters
Abstract
PMID: 22146436

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Patent-sharing scheme for neglected diseases may have catch.
Hannah Waters
Abstract
PMID: 22146436

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Patent-sharing scheme for neglected diseases may have catch.
Hannah Waters
Abstract
PMID: 22146436

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Pádraig D'Arcy, Slavica Brnjic, Maria Hägg Olofsson, Mårten Fryknäs, Kristina Lindsten, Michelandrea De Cesare, Paola Perego, Behnam Sadeghi, Moustapha Hassan, Rolf Larsson and Stig Linder
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH... | PMID: 22057347

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
Merit Cudkowicz, Michael E Bozik, Evan W Ingersoll, Robert Miller, Hiroshi Mitsumoto, Jeremy Shefner, Dan H Moore, David Schoenfeld, James L Mather, Donald Archibald, Mary Sullivan, Craig Amburgey, Juliet Moritz and Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In... | PMID: 22101764

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
New HCV drugs trigger race for more tolerable therapies.
Sarah C P Williams
Abstract
PMID: 22146431

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Four-in-one HIV pill may be exception among combination drugs.
Hannah Waters
Abstract
PMID: 22146434

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Class of once-weekly diabetes drugs poised for approval.
Hannah Waters
Abstract
PMID: 22146435

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Patent-sharing scheme for neglected diseases may have catch.
Hannah Waters
Abstract
PMID: 22146436

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Pádraig D'Arcy, Slavica Brnjic, Maria Hägg Olofsson, Mårten Fryknäs, Kristina Lindsten, Michelandrea De Cesare, Paola Perego, Behnam Sadeghi, Moustapha Hassan, Rolf Larsson and Stig Linder
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH... | PMID: 22057347

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
Merit Cudkowicz, Michael E Bozik, Evan W Ingersoll, Robert Miller, Hiroshi Mitsumoto, Jeremy Shefner, Dan H Moore, David Schoenfeld, James L Mather, Donald Archibald, Mary Sullivan, Craig Amburgey, Juliet Moritz and Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In... | PMID: 22101764

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
New HCV drugs trigger race for more tolerable therapies.
Sarah C P Williams
Abstract
PMID: 22146431

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Four-in-one HIV pill may be exception among combination drugs.
Hannah Waters
Abstract
PMID: 22146434

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Class of once-weekly diabetes drugs poised for approval.
Hannah Waters
Abstract
PMID: 22146435

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Patent-sharing scheme for neglected diseases may have catch.
Hannah Waters
Abstract
PMID: 22146436

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Pádraig D'Arcy, Slavica Brnjic, Maria Hägg Olofsson, Mårten Fryknäs, Kristina Lindsten, Michelandrea De Cesare, Paola Perego, Behnam Sadeghi, Moustapha Hassan, Rolf Larsson and Stig Linder
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH... | PMID: 22057347

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
Merit Cudkowicz, Michael E Bozik, Evan W Ingersoll, Robert Miller, Hiroshi Mitsumoto, Jeremy Shefner, Dan H Moore, David Schoenfeld, James L Mather, Donald Archibald, Mary Sullivan, Craig Amburgey, Juliet Moritz and Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In... | PMID: 22101764

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
New HCV drugs trigger race for more tolerable therapies.
Sarah C P Williams
Abstract
PMID: 22146431

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Four-in-one HIV pill may be exception among combination drugs.
Hannah Waters
Abstract
PMID: 22146434

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Class of once-weekly diabetes drugs poised for approval.
Hannah Waters
Abstract
PMID: 22146435

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Patent-sharing scheme for neglected diseases may have catch.
Hannah Waters
Abstract
PMID: 22146436

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Pádraig D'Arcy, Slavica Brnjic, Maria Hägg Olofsson, Mårten Fryknäs, Kristina Lindsten, Michelandrea De Cesare, Paola Perego, Behnam Sadeghi, Moustapha Hassan, Rolf Larsson and Stig Linder
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH... | PMID: 22057347

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
Merit Cudkowicz, Michael E Bozik, Evan W Ingersoll, Robert Miller, Hiroshi Mitsumoto, Jeremy Shefner, Dan H Moore, David Schoenfeld, James L Mather, Donald Archibald, Mary Sullivan, Craig Amburgey, Juliet Moritz and Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In... | PMID: 22101764

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
New HCV drugs trigger race for more tolerable therapies.
Sarah C P Williams
Abstract
PMID: 22146431

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Four-in-one HIV pill may be exception among combination drugs.
Hannah Waters
Abstract
PMID: 22146434

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Class of once-weekly diabetes drugs poised for approval.
Hannah Waters
Abstract
PMID: 22146435

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Patent-sharing scheme for neglected diseases may have catch.
Hannah Waters
Abstract
PMID: 22146436

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Pádraig D'Arcy, Slavica Brnjic, Maria Hägg Olofsson, Mårten Fryknäs, Kristina Lindsten, Michelandrea De Cesare, Paola Perego, Behnam Sadeghi, Moustapha Hassan, Rolf Larsson and Stig Linder
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH... | PMID: 22057347

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
Merit Cudkowicz, Michael E Bozik, Evan W Ingersoll, Robert Miller, Hiroshi Mitsumoto, Jeremy Shefner, Dan H Moore, David Schoenfeld, James L Mather, Donald Archibald, Mary Sullivan, Craig Amburgey, Juliet Moritz and Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In... | PMID: 22101764

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
New HCV drugs trigger race for more tolerable therapies.
Sarah C P Williams
Abstract
PMID: 22146431

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Four-in-one HIV pill may be exception among combination drugs.
Hannah Waters
Abstract
PMID: 22146434

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Class of once-weekly diabetes drugs poised for approval.
Hannah Waters
Abstract
PMID: 22146435

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Patent-sharing scheme for neglected diseases may have catch.
Hannah Waters
Abstract
PMID: 22146436

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Pádraig D'Arcy, Slavica Brnjic, Maria Hägg Olofsson, Mårten Fryknäs, Kristina Lindsten, Michelandrea De Cesare, Paola Perego, Behnam Sadeghi, Moustapha Hassan, Rolf Larsson and Stig Linder
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH... | PMID: 22057347

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
Merit Cudkowicz, Michael E Bozik, Evan W Ingersoll, Robert Miller, Hiroshi Mitsumoto, Jeremy Shefner, Dan H Moore, David Schoenfeld, James L Mather, Donald Archibald, Mary Sullivan, Craig Amburgey, Juliet Moritz and Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In... | PMID: 22101764

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
New HCV drugs trigger race for more tolerable therapies.
Sarah C P Williams
Abstract
PMID: 22146431

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Four-in-one HIV pill may be exception among combination drugs.
Hannah Waters
Abstract
PMID: 22146434

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Class of once-weekly diabetes drugs poised for approval.
Hannah Waters
Abstract
PMID: 22146435

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Patent-sharing scheme for neglected diseases may have catch.
Hannah Waters
Abstract
PMID: 22146436

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
Inhibition of proteasome deubiquitinating activity as a new cancer therapy.
Pádraig D'Arcy, Slavica Brnjic, Maria Hägg Olofsson, Mårten Fryknäs, Kristina Lindsten, Michelandrea De Cesare, Paola Perego, Behnam Sadeghi, Moustapha Hassan, Rolf Larsson and Stig Linder
Abstract
We describe the small molecule b-AP15 as a previously unidentified class of proteasome inhibitor that abrogates the deubiquitinating activity of the 19S regulatory particle. b-AP15 inhibited the activity of two 19S regulatory-particle-associated deubiquitinases, ubiquitin C-terminal hydrolase 5 (UCH... | PMID: 22057347

Large_pdficon_selected PDF is available here.
Nature Medicine (17)12 2011
The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis.
Merit Cudkowicz, Michael E Bozik, Evan W Ingersoll, Robert Miller, Hiroshi Mitsumoto, Jeremy Shefner, Dan H Moore, David Schoenfeld, James L Mather, Donald Archibald, Mary Sullivan, Craig Amburgey, Juliet Moritz and Valentin K Gribkoff
Abstract
We tested the putative mitochondrial modulator dexpramipexole (KNS-760704; (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine) in subjects with ALS in a two-part, double-blind safety and tolerability study, with a preliminary assessment of its effects on functional decline and mortality. In... | PMID: 22101764

Large_pdficon_selected PDF is available here.